Want to see IN:SANOFI full AI Analyst Report?
SANOFI Stock Chart & Stats
₹3387.70
-₹20.10(-0.59%)
At close: 4:00 PM EDT
₹3387.70
-₹20.10(-0.59%)
Day’s Range― - ―
52-Week Range₹3,057.60 - ₹5,922.45
Previous CloseN/A
Volume9.67K
Average Volume (3M)3.77K
Market Cap
₹77.43B
Enterprise Value₹91.66K
Total Cash (Recent Filing)₹2.75B
Total Debt (Recent Filing)₹178.00M
Price to Earnings (P/E)25.0
Beta0.73
Next Earnings
Aug 04, 2026EPS Estimate
39.3Next Dividend Ex-DateN/A
Dividend Yield3.6%
Share Statistics
EPS (TTM)98.01
Shares Outstanding23,030,000
10 Day Avg. Volume3,778
30 Day Avg. Volume3,766
Financial Highlights & Ratios
PEG Ratio6.96
Price to Book (P/B)12.56
Price to Sales (P/S)5.12
P/FCF Ratio22.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)168.05
Revenue Forecast (FY)₹19.50B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a strong ROE (~44% in 2025) provide durable financial flexibility. This balance-sheet strength supports investment in R&D and commercial execution, enables steadier dividend or buyback capacity, and helps absorb regulatory or demand shocks in the pharma sector over the medium term.
Strong Cash GenerationHigh free cash flow that tracks earnings and a large 2025 FCF uplift indicate earnings quality and reliable cash conversion. Robust FCF supports capital expenditure, marketing or launches, debt repayment and shareholder returns without dependence on volatile external financing, strengthening long-term resilience.
Sustained Operating ProfitabilityConsistently high operating margins imply an efficient cost structure and pricing power across therapy areas. Durable operating profitability underpins cash generation and competitive positioning, providing a buffer to invest in growth or withstand pricing and input-cost headwinds common in the pharma industry.
Bears Say
Weakening Revenue TrendA sustained top-line decline (2025 -4.1% and multi-year weakness) signals potential market-share loss, pricing pressure, or portfolio underperformance. Continued revenue contraction would impair scale economics, reduce reinvestment capacity for launches or marketing, and pressure long-term growth prospects.
Gross Margin CompressionA material fall in gross margin suggests structural cost pressures, adverse mix shifts, or pricing erosion versus prior years. Persistent margin compression reduces operating leverage and long-term earnings power, making it harder to sustain investment, dividends, or competitive pricing without margin-restoration actions.
Declining Equity BaseA meaningful drop in equity can artificially boost ROE while shrinking the capital buffer. A smaller equity base reduces resilience to shocks, limits financing flexibility for acquisitions or capex, and may indicate distributions or balance-sheet maneuvers that could constrain long-term strategic options.
Sanofi India Limited News
SANOFI FAQ
What was Sanofi India Limited’s price range in the past 12 months?
Sanofi India Limited lowest stock price was ₹3057.60 and its highest was ₹5922.45 in the past 12 months.
What is Sanofi India Limited’s market cap?
Sanofi India Limited’s market cap is ₹77.43B.
When is Sanofi India Limited’s upcoming earnings report date?
Sanofi India Limited’s upcoming earnings report date is Aug 04, 2026 which is in 4 days.
How were Sanofi India Limited’s earnings last quarter?
Sanofi India Limited released its earnings results on Apr 28, 2026. The company reported ₹44.5 earnings per share for the quarter, missing the consensus estimate of ₹44.6 by -₹0.1.
Is Sanofi India Limited overvalued?
According to Wall Street analysts Sanofi India Limited’s price is currently Overvalued.
Does Sanofi India Limited pay dividends?
Sanofi India Limited pays a Semiannually dividend of ₹48 which represents an annual dividend yield of 3.6%. See more information on Sanofi India Limited dividends here
What is Sanofi India Limited’s EPS estimate?
Sanofi India Limited’s EPS estimate is 39.3.
How many shares outstanding does Sanofi India Limited have?
Sanofi India Limited has 23,030,000 shares outstanding.
What happened to Sanofi India Limited’s price movement after its last earnings report?
Sanofi India Limited reported an EPS of ₹44.5 in its last earnings report, missing expectations of ₹44.6. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Sanofi India Limited?
Currently, no hedge funds are holding shares in IN:SANOFI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sanofi India Limited
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections, epilepsy, anti-infectives, and central nervous system, as well as allergy, pain care, digestive, and nutritional health under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products to approximately 24 countries. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited is a subsidiary of Hoechst GmbH.
Technical Analysis
Abbott India Limited
―
Cipla Ltd
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
PFIZER LIMITED
―